Orca Bio will present clinical data on its pipeline of high-precision cell therapies at the 52nd Annual Meeting of the EBMT
Patient-reported outcomes from the pivotal Precision-T Phase 3 study will be presented, including quality of life metrics and rehospitalization rates compared to conventional alloHSCT
Data will be shared evaluating Orca-T with reduced intensity conditioning versus post-transplant cyclophosphamide (PTCy) for treating hematologic malignancies
Presentations will highlight manufacturing and nationwide distribution data for Orca-T and clinical findings of Orca-Q in patients with haploidentical donors
An oral presentation titled 'Orca-T Demonstrates Favorable Quality of Life and Healthcare Resource Use Compared to Standard AlloHSCT plus Tac/MTX for GVHD Prevention in a Randomized Phase 3 Clinical Trial (Precision-T)' is scheduled for Wednesday, March 25 at 08:
30 AM CET in room N107
Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation from the FDA, with a Biologics License Application (BLA) currently under Priority Review with a PDUFA target action date of April 6, 2026